Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Men at High Genetic Risk for Prostate Cancer
Printer Friendly Page Men at High Genetic Risk for Prostate Cancer

Men at High Genetic Risk for Prostate Cancer identifier:

Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

Study Contact Information:

Anna Couvillon, Nurse Practitioner
By phone: (240) 858-3148
or by email 

Men at High Genetic Risk for Prostate Cancer

About the Study

The National Cancer Institute opened a clinical trial for cancer screening in men who are at high risk for cancer due to an

View the study on or contact Anna Couvillon, NP at: (240) 858-3148 or by email. 

What the Study Entails

  • Screening of the every 2 years
  • Annual blood test
  • Biopsy of the if any MRIs are abnormal
  • No cost for study-related tests or procedures
  • No cost for travel
  • Clinical information will be shared with you and your doctor, if you choose
  • Genetic testing is not offered as part of the study

Study Lead Investigator

Fatima Karzai, MD, National Cancer Institute (NCI)

Study Site

The National Institutes of Health (), Clinical Center
Bethesda, MD in the Washington, DC metro area
NIH can cover the cost of travel for participants


This Study is Open To:
  • Men, 30 to 75 years old without cancer who have tested positive for (, , , , ), , , , , , , , , , , , or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM) mutation.
  • Genetic testing is not offered.
This Study is Not Open To:
  • Men who have already been diagnosed with cancer